Clinical Trial Update: A Trial to Investigate the Efficacy and Safety of Orally Administered Tolvaptan (OPC-41061) in Patients With Chronic Renal Failure Undergoing Hemodialysis or Hemodiafiltration [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating oral tolvaptan (OPC-41061) for efficacy and safety in patients with chronic renal failure on hemodialysis/hemodiafiltration.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Renal Failure

Drugs mentioned

• tolvaptan (tolvaptan)

Snippet

Sponsor: Otsuka Pharmaceutical Co., Ltd. | Conditions: Chronic Renal Failure | Phase 2 | Status: COMPLETED | Results posted: 2019-10-22